The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
MeSH Review

Mastocytosis, Systemic

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Mastocytosis, Systemic


High impact information on Mastocytosis, Systemic


Chemical compound and disease context of Mastocytosis, Systemic


Biological context of Mastocytosis, Systemic


Anatomical context of Mastocytosis, Systemic


Gene context of Mastocytosis, Systemic


Analytical, diagnostic and therapeutic context of Mastocytosis, Systemic


  1. FIP1L1-PDGFRA fusion: prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia. Pardanani, A., Brockman, S.R., Paternoster, S.F., Flynn, H.C., Ketterling, R.P., Lasho, T.L., Ho, C.L., Li, C.Y., Dewald, G.W., Tefferi, A. Blood (2004) [Pubmed]
  2. Evidence for the involvement of a hematopoietic progenitor cell in systemic mastocytosis from single-cell analysis of mutations in the c-kit gene. Yavuz, A.S., Lipsky, P.E., Yavuz, S., Metcalfe, D.D., Akin, C. Blood (2002) [Pubmed]
  3. Activation mutations of human c-KIT resistant to imatinib mesylate are sensitive to the tyrosine kinase inhibitor PKC412. Growney, J.D., Clark, J.J., Adelsperger, J., Stone, R., Fabbro, D., Griffin, J.D., Gilliland, D.G. Blood (2005) [Pubmed]
  4. Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies. Schittenhelm, M.M., Shiraga, S., Schroeder, A., Corbin, A.S., Griffith, D., Lee, F.Y., Bokemeyer, C., Deininger, M.W., Druker, B.J., Heinrich, M.C. Cancer Res. (2006) [Pubmed]
  5. Tetany, malabsorption, and mastocytosis. Dantzig, P.I. Arch. Intern. Med. (1975) [Pubmed]
  6. Treatment of systemic mast-cell disease with cladribine. Tefferi, A., Li, C.Y., Butterfield, J.H., Hoagland, H.C. N. Engl. J. Med. (2001) [Pubmed]
  7. Tryptase levels as an indicator of mast-cell activation in systemic anaphylaxis and mastocytosis. Schwartz, L.B., Metcalfe, D.D., Miller, J.S., Earl, H., Sullivan, T. N. Engl. J. Med. (1987) [Pubmed]
  8. Abnormal histamine-induced suppressor-cell function in atopic subjects. Beer, D.J., Osband, M.E., McCaffrey, R.P., Soter, N.A., Rocklin, R.E. N. Engl. J. Med. (1982) [Pubmed]
  9. Secretory diarrhea and prostaglandin D2 overproduction in systemic mastocytosis. Poynard, T., Nataf, C., Messing, B., Modigliani, R., Lecompte, T., Nicolas, P., Dray, F., Ferme, C. N. Engl. J. Med. (1982) [Pubmed]
  10. Oral disodium cromoglycate in the treatment of systemic mastocytosis. Soter, N.A., Austen, K.F., Wasserman, S.I. N. Engl. J. Med. (1979) [Pubmed]
  11. Treatment of adult systemic mastocytosis with a PAF-acether antagonist BN52063. Guinot, P., Summerhayes, C., Berdah, L., Duchier, J., Revillaud, R.J. Lancet (1988) [Pubmed]
  12. Effect of cimetidine on gastric hypersecretion and diarrhea in systemic mastocytosis. Hirschowitz, B.I., Groarke, J.F. Ann. Intern. Med. (1979) [Pubmed]
  13. Heparin activity in systemic mastocytosis. Campbell, E.W., Hector, D., Gossain, V. Ann. Intern. Med. (1979) [Pubmed]
  14. Mithramycin in the treatment of systemic mastocytosis. Conrad, M.E., Carpenter, J.T., Todd, J.N., Murad, T.M. Ann. Intern. Med. (1975) [Pubmed]
  15. Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation. Gotlib, J., Berubé, C., Growney, J.D., Chen, C.C., George, T.I., Williams, C., Kajiguchi, T., Ruan, J., Lilleberg, S.L., Durocher, J.A., Lichy, J.H., Wang, Y., Cohen, P.S., Arber, D.A., Heinrich, M.C., Neckers, L., Galli, S.J., Gilliland, D.G., Coutré, S.E. Blood (2005) [Pubmed]
  16. Multilineage involvement and erythropoietin-"independent" erythroid progenitor cells in a patient with systemic mastocytosis. Afonja, O., Amorosi, E., Ashman, L., Takeshita, K. Ann. Hematol. (1998) [Pubmed]
  17. The effect of pamidronate on lumbar spine bone density and pain in osteoporosis secondary to systemic mastocytosis. Marshall, A., Kavanagh, R.T., Crisp, A.J. Br. J. Rheumatol. (1997) [Pubmed]
  18. Bronchial hyperresponsiveness in a patient with systemic mastocytosis. Mochizuki, H., Morikawa, A., Kurosawa, M. Respirology (2002) [Pubmed]
  19. Cimetidine in systemic mastocytosis. Berg, M.J., Bernhard, H., Schentag, J.J. Drug intelligence & clinical pharmacy. (1981) [Pubmed]
  20. The alpha form of human tryptase is the predominant type present in blood at baseline in normal subjects and is elevated in those with systemic mastocytosis. Schwartz, L.B., Sakai, K., Bradford, T.R., Ren, S., Zweiman, B., Worobec, A.S., Metcalfe, D.D. J. Clin. Invest. (1995) [Pubmed]
  21. Expression, epitope analysis, and functional role of the LFA-2 antigen detectable on neoplastic mast cells. Schernthaner, G.H., Jordan, J.H., Ghannadan, M., Agis, H., Bevec, D., Nuñez, R., Escribano, L., Majdic, O., Willheim, M., Worda, C., Printz, D., Fritsch, G., Lechner, K., Valent, P. Blood (2001) [Pubmed]
  22. Effect of granulocyte macrophage colony-stimulating factor in a patient with benign systemic mastocytosis. Zuberbier, T., Welker, P., Grabbe, J., Henz, B.M. Br. J. Dermatol. (2001) [Pubmed]
  23. Clinical advances in mastocytosis. Genovese, A., Spadaro, G., Triggiani, M., Marone, G. Int. J. Clin. Lab. Res. (1995) [Pubmed]
  24. CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy. Pardanani, A., Ketterling, R.P., Brockman, S.R., Flynn, H.C., Paternoster, S.F., Shearer, B.M., Reeder, T.L., Li, C.Y., Cross, N.C., Cools, J., Gilliland, D.G., Dewald, G.W., Tefferi, A. Blood (2003) [Pubmed]
  25. Vesicular monoamine transporter 2 (VMAT2) expression in hematopoietic cells and in patients with systemic mastocytosis. Anlauf, M., Schäfer, M.K., Schwark, T., von Wurmb-Schwark, N., Brand, V., Sipos, B., Horny, H.P., Parwaresch, R., Hartschuh, W., Eiden, L.E., Klöppel, G., Weihe, E. J. Histochem. Cytochem. (2006) [Pubmed]
  26. Analysis of the wheal-and-flare reactions that follow the intradermal injection of histamine and morphine in adults with recurrent, unexplained anaphylaxis and systemic mastocytosis. Keffer, J.M., Bressler, R.B., Wright, R., Kaliner, M.A., Metcalfe, D.D. J. Allergy Clin. Immunol. (1989) [Pubmed]
  27. Utility of paraffin section immunohistochemistry for C-KIT (CD117) in the differential diagnosis of systemic mast cell disease involving the bone marrow. Natkunam, Y., Rouse, R.V. Am. J. Surg. Pathol. (2000) [Pubmed]
  28. Serum tryptase and the laboratory diagnosis of systemic mastocytosis. Schwartz, L.B., Irani, A.M. Hematol. Oncol. Clin. North Am. (2000) [Pubmed]
  29. Detection of molecular targets on the surface of CD34+/CD38-- stem cells in various myeloid malignancies. Florian, S., Sonneck, K., Hauswirth, A.W., Krauth, M.T., Schernthaner, G.H., Sperr, W.R., Valent, P. Leuk. Lymphoma (2006) [Pubmed]
  30. Detection of c-kit mutation Asp 816 to Val in microdissected bone marrow infiltrates in a case of systemic mastocytosis associated with chronic myelomonocytic leukaemia. Sotlar, K., Marafioti, T., Griesser, H., Theil, J., Aepinus, C., Jaussi, R., Stein, H., Valent, P., Horny, H.P. MP, Mol. Pathol. (2000) [Pubmed]
WikiGenes - Universities